Chemical In Gut May Help Fight Obesity InjuryBoard.com, FL - Overweight and obese individuals are at increased risk for many diseases and health conditions such as high blood pressure, osteoarthritis, high cholesterol...
Got low cholesterol? Statins still might help The Oregonian - OregonLive.com, OR - Nov 26, 2008 And it does expand our target group of patients for statins. More knowledge is important because about half of heart attacks occur in patients with low ...
Citigroup analyst cuts target for Merck sales, EPS Forbes, NY - Nov 26, 2008 He forecast that weekly prescriptions for Vytorin and Zetia, the cholesterol drugs Merck jointly sells with partner Schering-Plough Corp., would be down by ...MRK
Newfield Reports Second Quarter 2008 Financial Results PR Newswire (press release), NY - Jul 23, 2008 The Company has also contracted two new build rigs that will increase its operated rig count to 17 rigs in the second half of 2009. Newfield expects to move ...NFX
유가 이틀 연속 급락?WTI 134.6달러 EBN뉴스센터, South Korea - Jul 16, 2008 EIA는 주간 석유재고 조사 결과 11일 기준 원유재고가 전주대비 300만배럴 증가한 2억9천690만배럴을 기록했다고 발표했다. 이는 일평균 원유 수입량이 전주대비 일일 ...
2004年重庆市教育概况 挖贝网, China - Jul 18, 2008 全市有独立设置成人高校11所，教职工0.33万人,其中专任教师0.2万人。独立成人高校和普通本专科院校共计招生5.4万人（其中本科1.8万人、专科3.6万人），在校生9.6万 ...
Different Forms of Adrenal Phenylethanolamine N-Methyltransferase: Species-Specific … - DH Park, EE Baetge, BB Kaplan, VR Albert, DJ Reis, … - Journal of Neurochemistry, 1982 - Blackwell Synergy ... L-methionine (57.3 mCi/mmol), rabbit reticulocyte lysate, and Aquassure were obtained
from New England Nuclear (Boston, MA ... SephadexG 100 0.33690 2090 4.5 116 - ...
BV 690, a new bright Type II Cepheid - NB Sanwal, MBK Sarma - Journal of Astrophysics and Astronomy, 1991 - Springer ... BV 690, a new bright Type II Cepheid 129 ... On the other hand if we assume BV 690 to
be a Type ... This yields an intrinsic colour of 0.33, which is also outside the ... -
New Series of Rock and Sediment Geochemical Reference Materials C Wang, T Gu, Q Chi, W Yan, M Yan - Geostandards and Geoanalytical Research, 2001 - Blackwell Synergy ...New Series of Rock and Sediment ... 57 5 10 S (50) - - Sb 0.063 0.010 7 Sc 5.0 0.4 6
Se 0.019 0.005 7 Sm 3.3 0.3 7 Sn 0.8 0.2 7 Sr 690 20 6 Ta (0.33) - - Tb 0.29 ...
Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients - E Fokkema, EGE de Vries, S Meijer, HJM Groen - Cancer Chemotherapy and Pharmacology, 2000 - Springer ... has been developed in the search for new platinum drugs ... 228?709 ml/min) and 0.28
(0.21?0.33), respectively. ... Life Sci 32: 685?690 8. Goren MP, Forastiere AA ...
[CITATION] Synthesis and Properties of New Donor-Acceptor-Acccptor Triads based on Pyrazolino [60] Fullerene. F Langa, P de la Cruz, JL Delgado, MJ Gomez- … - Fullerenes for the New Millennium: Proceedings of the …, 2001 - The Electrochemical Society
Mannich bases of 4-phenyl-3-buten-2-one. A new class of antiherpes agent - ML Edwards, HW Ritter, DM Stemerick, KT Stewart - Journal of Medicinal Chemistry, 1983 - pubs.acs.org ... Chem. 1983,26, 431-436 43 1 Mannich Bases of 4-Phenyl-3-buten-2-one: A New Class
of Antiherpes Agent ... 44f SO,CH, disodium phosphonoacetate 0.33-0.67 74-88 ...
PCSK9 protein, a new target for cholesterol-lowering drugs
Mice lacking a key protein involved in cholesterol regulation have low-density lipoprotein ( LDL ) levels more than 50 percent lower than normal mice, and researchers suggest that inhibiting the same protein in humans could lead to new cholesterol-lowering drugs.
In a study, published in the Proceedings of the National Academy of Sciences ( PNAS ), researchers at UT Southwestern Medical Center deleted the Pcsk9 gene in mice. The gene, present in both mice and humans, makes the PCSK9 protein, which normally gets rid of receptors that latch onto LDL cholesterol in the liver. Without this degrading protein, the mice had more LDL receptors and were thus able to take up more LDL cholesterol from their blood.
" The expression of LDL receptors is the primary mechanism by which humans lower LDL cholesterol in the blood," said Jay Horton, senior author of the study. " This research shows that in mice, deleting the PCSK9 protein results in an increase in LDL receptors and a significant lowering of LDL cholesterol."
High LDL cholesterol is a major risk factor for heart disease, heart attack and stroke because it contributes to the buildup of plaque that clogs the walls of arteries. Nearly 25 million people worldwide take a class of drugs called statins to lower their cholesterol to within recommended healthy levels.
On average, mice lacking the Pcsk9 gene had blood LDL cholesterol levels of 46 milligrams per deciliter, while wild-type mice had levels around 96 mg/dl, a difference of 52 percent.
Horton's research is consistent with findings from another recent UT Southwestern study showing that humans with mutations in their PCSK9 gene, which prevented them from making normal levels of PCSK9 protein, had LDL cholesterol levels 40 percent lower than individuals without the mutation. That study, based on data gathered from nearly 6,000 participants in the Dallas Heart Study, was published in Nature Genetics.
" The lower cholesterol levels of humans with mutations in PCSK9, combined with the results of our studies in mice, suggest that variations in the levels of the PCSK9 protein significantly affect blood cholesterol levels, and compounds that inhibit this protein may be useful for the treatment of high cholesterol," Horton said.
Horton and his colleagues also gave their knockout mice statins, which further enhanced the clearance of LDL cholesterol from their blood. The findings suggest new drugs targeting PCSK9 may be able to act in conjunction with statin drugs to further lower LDL cholesterol levels.
Horton said cholesterol-lowering drugs based on blocking PCSK9 might be effective on their own as well, providing another option for individuals unable to take statins.
Statins increase the activity of a protein called SREBP-2, which activates the creation of more LDL receptors; however, Horton's previous studies found that SREBP-2 also boosts the activity of the PCSK9 protein, which degrades those receptors.
" We looked at these competing effects and thought that if we removed the PCSK9 component completely, we would get a further increase in LDL receptors, and that's what happened," he said.
The competing systems may have evolved to keep the body's cholesterol levels fine-tuned and to minimize big swings in cholesterol content in normal cells, Horton said. Too much or too little cholesterol can damage or kill cells. He and his colleagues next will try to determine just how the PCSK9 protein degrades the LDL receptors.
Source: University of Texas Southwestern Medical Center, 2005
Comment by Elizabeth G. Nabel M.D.